Lucentis Made Available

Thousands of Belgian patients could be saved from going blind after US firm Genentech's controversial drug Lucentis (ranibizumab), which treats wet age-related macular degeneration (AMD), was made available in the country, with the state picking up the lion's share of the cost.

To read the full article, please choose one of the following options: